Kuboshima Mari, Shimada Hideaki, Liu Tian-Ling, Nakashima Kazue, Nomura Fumio, Takiguchi Masaki, Hiwasa Takaki, Ochiai Takenori
Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan.
Int J Oncol. 2006 Feb;28(2):463-8.
We have carried out SEREX (serological identification of antigens by recombinant cDNA expression cloning), and identified SLC2A1 (solute carrier family 2/facilitated glucose transporter, member 1) as an antigen recognized by serum IgG antibodies in patients with esophageal squamous cell carcinoma (SCC). The levels of serum anti-SLC2A1 antibodies (s-SLC2A1-Abs), examined by enzyme-linked immunosorbent assay using bacterially expressed glutathione-S-transferase-SLC2A1 fusion protein, were significantly higher in patients with esophageal SCC than in healthy donors. When using a cut-off level as the mean + 2x standard deviations of healthy donors, a total of 12 (21%) out of 57 SCC patients were revealed as positive for s-SLC2A1-Abs. The presence of s-SLC2A1-Abs was not associated with either clinicopathological factors or survival. Because s-SLC2A1-Abs were not associated with the positivity of other conventional serum markers, a combination assay of s-SLC2A1-Abs with these conventional serum markers may be useful for the diagnosis and monitoring of esophageal SCC.
我们开展了SEREX（通过重组cDNA表达克隆进行抗原的血清学鉴定），并将溶质载体家族2/易化葡萄糖转运蛋白成员1（SLC2A1）鉴定为食管鳞状细胞癌（SCC）患者血清IgG抗体识别的一种抗原。使用细菌表达的谷胱甘肽-S-转移酶-SLC2A1融合蛋白通过酶联免疫吸附测定检测的血清抗SLC2A1抗体（s-SLC2A1-Abs）水平，在食管SCC患者中显著高于健康供者。当以健康供者的平均值+2倍标准差作为临界值时，57例SCC患者中有12例（21%）被检测出s-SLC2A1-Abs呈阳性。s-SLC2A1-Abs的存在与临床病理因素或生存率均无关联。由于s-SLC2A1-Abs与其他传统血清标志物的阳性结果无关，因此s-SLC2A1-Abs与这些传统血清标志物的联合检测可能有助于食管SCC的诊断和监测。
